|  |  |
| --- | --- |
| **Pre-Program Activities**  | **Pre-Lecture 1 – Viral Hepatitis –**A summary for discovery and natural history of HCV 60 min**Pre-Lecture 2 - End Stage Liver Disease**: An overview of Treatment, Managing Complications chronic liver disease, cirrhosis, and the transplant process – 45 min |
| **7:30 am** | ***Registration and View Exhibits*** |
| **8:00 am** | **Opening Comments and Pre-Test** |
| **8:15 am**  | **Review of Viral Hepatitis –HCV*** Highlight of Pre-Lecture 1
* Screening and Treatment of HCV
* Clinical Cases and Discussion
 |
| **9:00 am** | **Hepatitis B: Epidemiology, Natural History and Testing** * The epidemiology of the Hepatitis B infection
* Efficacies and opportunities in HBV testing and vaccination
* Anti-viral therapies of HBV
* The growing relationship between HBV and HDV
 |
| **9:30 am**  | ***Product Theater # 1 Break and View exhibits*** |
| **10:10 am** | **Delta Hepatitis and Hepatitis E Update** * Worldwide perspective and promising research studies
* Real world outcome studies on HDV and HEV
 |
| **10:40 am** | **End Stage Liver Disease: Recap and Clinical Cases** * A review of Pre-course lecture on end-stage liver disease
* Clinical cases to illustrate HE and Thrombocytopenia
 |
| **11:20 am** | **Hepatocellular Carcinoma (HCC)** * Screening diagnostic serum assays and imaging tests
* Treatment and management options: Ablation, TACE and Surgery
 |
| **11:50 am** | **Hepatocellular Carcinoma: New Systemic Treatment Options** * **A case-based approach to HCC treatment**
* Current FDA-Approved Therapies
* New chemotherapy regimens in development and testing Immunotherapy as the new MoA for HCC
 |
| **12:20 pm** | ***Luncheon and Industry Presentation #2***  |
| **1:00pm** | ***Dessert and View Exhibits*** |
| **1:10 pm** | **Cholestatic Liver Disease: and Primary Biliary Cholangitis and Primary Sclerosing Cholangitis (PSC)** * Epidemiology of PSC and Ursodiol and Antibiotic Treatments
* Predicting outcomes and Improving Survival in PSC patients
* Causes and Markers of PBC
* Ursodeoxycholic Acid (UDCA) and Obeticholic Acid
 |
| **1:50 pm** | **Alcohol Associated Liver Disease** * The growing prevalence of alcohol over-consumption and its impact on liver health
* Warning signs and intervention in alcohol-associated hepatitis
 |
| **2:20 pm** | **Fluid Management, Ascites and Hepatorenal Syndrome** * The diagnosis and treatment of ascites
* How cirrhosis can lead to portal hypertension, ascites, kidney disease and hepatorenal syndrome
* New and emerging treatment approaches for of HRS
 |
| ***2:50 pm*** | ***Break & View Exhibits*** |
| **3:00 pm** | **NAFLD and NASH** * Epidemiology, Demographics and Diagnosis
* Scoring, Staging and Management of Fatty Liver Disease
* Treatment options for thrombocytopenia; including alternatives to platelet transfusion.
 |
| **3:30 pm** | **NASH Treatments in Practice and in Development** * Current therapies for NASH including Updates from AASLD and EASL
* Lifestyle changes as a therapy
* Drugs in clinical development for NASH
 |
| **4:15 pm** | **Closing Comments, Post-test and Wrap-Up** Program **adjourns at 4:30 pm** |
| **Post-program activities**  | **Lecture 3 - SARS-CoV-2 and its Effect on the Liver** – 45 minutes**Lecture 4** – **The Resurgence of HAV and the Steps to Reverse this Trend –** 30 minutes**Lecture 5** - **Overcoming barriers to liver health in special populations** - 45 minutes |

**Course Directors: Paul J. Pockros, MD - Scripps Clinic**

 **Catherine Frenette, MD – Scripps Center for Cell and Organ Transplantation**

**Peer Review:**  **Tracy Ander, DO - University of Louisville School of Medicine**